Focinvez is a drug owned by Steriscience Pte Ltd. It is protected by 3 US drug patents filed from 2023 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 11, 2039. Details of Focinvez's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11065256 | Administration and dosage of diaminophenothiazines |
Jan, 2039
(13 years from now) | Active |
| US12042504 | Injectable fosaprepitant composition |
Jan, 2039
(13 years from now) | Active |
| US11065265 | Compositions of fosaprepitant and methods of preparation |
Jan, 2039
(13 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Focinvez's patents.
Latest Legal Activities on Focinvez's Patents
Given below is the list of recent legal activities going on the following patents of Focinvez.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed
Critical | 20 Jul, 2021 | US11065256 |
| Recordation of Patent Grant Mailed
Critical | 20 Jul, 2021 | US11065265 |
| Patent Issue Date Used in PTA Calculation
Critical | 20 Jul, 2021 | US11065256 |
| Patent Issue Date Used in PTA Calculation
Critical | 20 Jul, 2021 | US11065265 |
| Email Notification
Critical | 01 Jul, 2021 | US11065265 |
| Email Notification
Critical | 01 Jul, 2021 | US11065256 |
| Issue Notification Mailed
Critical | 30 Jun, 2021 | US11065265 |
| Issue Notification Mailed
Critical | 30 Jun, 2021 | US11065256 |
| Mail Response to 312 Amendment (PTO-271)
Critical | 25 Jun, 2021 | US11065256 |
| Email Notification
Critical | 25 Jun, 2021 | US11065256 |
US patents provide insights into the exclusivity only within the United States, but
Focinvez is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Focinvez's family patents as well as insights into
ongoing legal events
on those patents.
Focinvez's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Focinvez's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 11, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Focinvez Generic API suppliers:
Fosaprepitant Dimeglumine is the generic name for the brand Focinvez. 18 different companies have already filed for the generic of Focinvez, with Mylan Labs Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Focinvez's generic
Alternative Brands for Focinvez
There are several other brand drugs using the same active ingredient (Fosaprepitant Dimeglumine) as Focinvez. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Merck And Co Inc |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Fosaprepitant Dimeglumine, Focinvez's active ingredient. Check the complete list of approved generic manufacturers for Focinvez
About Focinvez
Focinvez is a drug owned by Steriscience Pte Ltd. Focinvez uses Fosaprepitant Dimeglumine as an active ingredient. Focinvez was launched by Steriscience in 2023.
Approval Date:
Focinvez was approved by FDA for market use on 22 August, 2023.
Active Ingredient:
Focinvez uses Fosaprepitant Dimeglumine as the active ingredient. Check out other Drugs and Companies using Fosaprepitant Dimeglumine ingredient
Dosage:
Focinvez is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 150MG BASE/50ML (EQ 3MG BASE/ML) | SOLUTION | Prescription | INTRAVENOUS |